Education
About Us
Working with TipRanks
Follow Us
Gossamer Bio Inc (GOSS)
NASDAQ:GOSS
Top Page
Gossamer Bio
(NASDAQ:GOSS)
33Underperform
Positive Factors
Market opportunity
Upcoming expansion into PH-ILD may unlock blockbuster potential, in the view of the management.
Partnerships
The strategic collaboration with Chiesi for the co-development and commercialization of seralutinib in PAH and PH-ILD further validates the potential of the program and strengthens its financial position.
Therapeutic potential
Seralutinib may offer a compelling alternative to IV therapies in the evolving PAH treatment paradigm, particularly for patients and physicians concerned about monitoring burden and side effects.
Negative Factors
Clinical trial results
The topline Ph.2 TORREY study data disappointed, although there were encouraging signals in severe patients.
Investor sentiment
Investor sentiment on GOSS has greatly contracted following Phase 2 TORREY data, making some wonder if the company can pull off a win.
Market competition
Our recent MEDACorp survey suggests that ~25% of patients need additional therapies such as GOSS's seralutinib despite the availability of Winrevair.
Gossamer Bio (GOSS) vs. S&P 500 (SPY)
Market Cap
$225.93M
Dividend YieldN/A
Average Volume (3M)1.61M
Price to Earnings (P/E)―
Beta (1Y)1.99
Revenue GrowthN/A
EPS Growth81.94%
CountryUS
Employees144
SectorHealthcare
Sector Strength78
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.26
Shares Outstanding227,221,270
10 Day Avg. Volume1,480,183
30 Day Avg. Volume1,611,805
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.75
Price to Cash Flow (P/CF)-2.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$8.75Price Target Upside993.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Gossamer Bio Business Overview & Revenue Model
Company DescriptionGossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
How the Company Makes MoneyGossamer Bio makes money primarily through the development and eventual commercialization of its proprietary therapeutic candidates. The company's revenue model is heavily reliant on the successful progression of its drug candidates through clinical trials, followed by regulatory approval and market entry. Key revenue streams include potential milestone payments, licensing agreements, and royalties from partnerships with larger pharmaceutical companies. Additionally, Gossamer Bio may generate income through strategic collaborations that provide funding for research and development activities, as well as potential future sales of approved drugs. The company's earnings are significantly influenced by the successful navigation of the regulatory landscape and the potential market demand for its therapies upon approval.
Gossamer Bio Financial Statement Overview
Summary
Gossamer Bio faces significant financial challenges, including high leverage and consistent losses. Despite a revenue increase in 2024, the company remains unprofitable, with minimal equity compared to liabilities and negative cash flow, indicating a need for substantial improvement in financial health.Income Statement
Gossamer Bio showed a significant revenue increase in 2024, but the company remains unprofitable with negative net income, EBIT, and EBITDA margins. The gross profit margin is nonexistent in prior years due to no revenue, indicating historical financial struggles.20
Very Negative
Balance Sheet
The company has a very high debt-to-equity ratio and negative equity in previous years, suggesting high financial leverage and risk. While equity became positive in 2024, it remains minimal compared to total liabilities, indicating ongoing financial instability.15
Very Negative
Cash Flow
Operating cash flow is consistently negative, reflecting poor cash generation relative to net income. However, the significant improvement in free cash flow in 2024 suggests efforts to stabilize cash flow, although it remains negative.25
Negative
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 114.70M | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
| 114.70M | -4.38M | -4.43M | -5.17M | -4.27M | EBIT |
| -59.92M | -183.76M | -218.59M | -216.12M | -233.96M | EBITDA |
| -39.97M | -172.15M | -211.07M | -209.32M | -233.96M | Net Income Common Stockholders |
| -56.53M | -179.82M | -240.23M | -249.08M | -251.58M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 294.52M | 296.43M | 255.68M | 325.22M | 512.63M | Total Assets |
| 315.29M | 311.92M | 272.45M | 343.66M | 539.43M | Total Debt |
| 202.88M | 212.46M | 225.74M | 185.24M | 183.73M | Net Debt |
| 156.81M | 180.35M | 113.77M | 1.83M | -302.32M | Total Liabilities |
| 285.80M | 249.15M | 260.37M | 222.19M | 218.75M | Stockholders Equity |
| 29.49M | 62.77M | -1.03B | -811.53M | -577.53M |
| Cash Flow | Free Cash Flow | |||
| -3.47M | -159.16M | -187.51M | -190.51M | -201.24M | Operating Cash Flow |
| -3.47M | -159.16M | -187.03M | -188.89M | -176.36M | Investing Cash Flow |
| 29.02M | -110.97M | -1.03M | -117.43M | 215.34M | Financing Cash Flow |
| -11.49M | 190.15M | 117.09M | 3.33M | 312.54M |
Gossamer Bio Technical Analysis
Negative
0.80
Price Trends
1.19
Negative
1.01
Negative
0.98
Negative
Market Momentum
-0.03
Positive
34.56
Neutral
8.31
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GOSS, the sentiment is Negative. The current price of 0.8 is below the 20-day moving average (MA) of 1.21, below the 50-day MA of 1.19, and below the 200-day MA of 0.98, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 34.56 is Neutral, neither overbought nor oversold. The STOCH value of 8.31 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GOSS.
Gossamer Bio Risk Analysis
Gossamer Bio disclosed 77 risk factors in its most recent earnings report. Gossamer Bio reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Gossamer Bio Peers Comparison
Overall Rating
UnderperformOutperform
Sector (48)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $221.94M | ― | -36.07% | ― | ― | -7.93% | |
50 Neutral | $239.58M | ― | -31.16% | ― | ― | 15.17% | |
48 Neutral | $6.86B | 1.11 | -50.22% | 2.47% | 16.71% | 1.53% | |
46 Neutral | $248.02M | ― | -33.88% | ― | ― | -22.66% | |
44 Neutral | $203.40M | ― | -29.56% | ― | ― | 10.98% | |
34 Underperform | $200.77M | ― | -50.84% | ― | ― | 43.21% | |
33 Underperform | $225.93M | ― | -122.54% | ― | ― | 81.94% |
* Healthcare Sector Average
Performance Comparison
GOSS
Gossamer Bio
0.80
-0.28
-25.93%
IMMP
Immutep
1.50
-1.28
-46.04%
ANNX
Annexon Biosciences
1.69
-4.36
-72.07%
AVIR
Atea Pharmaceuticals
2.79
-0.97
-25.80%
CMPX
Compass Therapeutics
1.46
-0.24
-14.12%
TERN
Terns Pharmaceuticals
2.10
-3.41
-61.89%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.